Cytokinetics Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Cytokinetics
CYTK Stock  USD 63.36  1.02  1.64%   
Analyzing historical trends in various income statement and balance sheet accounts from Cytokinetics' financial statements helps investors evaluate the company's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Cytokinetics' valuation are summarized below:
Gross Profit
-318 M
Market Capitalization
7.6 B
Enterprise Value Revenue
90.084
Revenue
87.2 M
Earnings Share
(6.30)
There are currently one hundred twenty fundamental signals for Cytokinetics that can be evaluated and compared over time across rivals. We recommend to validate Cytokinetics' prevailing fundamental drivers against the all of the trends between 2010 and 2026. Market Cap is expected to rise to about 7.6 B this year. Enterprise Value is expected to rise to about 334.5 M this year

Cytokinetics Total Revenue

32.49 Million

Check Cytokinetics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cytokinetics' main balance sheet or income statement drivers, such as Interest Expense of 104.5 M, Other Operating Expenses of 669.8 M or Research Development of 409.8 M, as well as many indicators such as Price To Sales Ratio of 269, Dividend Yield of 0.0 or Days Sales Outstanding of 299. Cytokinetics financial statements analysis is a perfect complement when working with Cytokinetics Valuation or Volatility modules.
  
Build AI portfolio with Cytokinetics Stock
Check out the analysis of Cytokinetics Correlation against competitors.
For more information on how to buy Cytokinetics Stock please use our How to buy in Cytokinetics Stock guide.

Cytokinetics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets1.7 B1.6 B553.5 M
Slightly volatile
Short and Long Term Debt Total952.3 M907 M286.9 M
Slightly volatile
Other Assets9.5 M8.7 M12.3 M
Very volatile
Common Stock Shares Outstanding135.2 M128.8 M61.2 M
Slightly volatile
Liabilities And Stockholders Equity1.7 B1.6 B553.5 M
Slightly volatile
Non Current Liabilities Total1.6 B1.6 B492.3 M
Slightly volatile
Other Stockholder Equity3.1 B2.9 B1.2 B
Slightly volatile
Total Liabilities1.9 B1.8 B557 M
Slightly volatile
Other Current Liabilities92.3 M87.9 M30.7 M
Slightly volatile
Total Current Liabilities217 M206.6 M65.3 M
Slightly volatile
Other Liabilities362.9 M345.6 M150.7 M
Slightly volatile
Property Plant And Equipment Net170.2 M162.1 M58.1 M
Slightly volatile
Current Deferred Revenue63.2 M60.2 M21.6 M
Slightly volatile
Accounts Payable24.6 M23.4 M10.5 M
Slightly volatile
Cash56.1 M109.1 M62.4 M
Slightly volatile
Non Current Assets Total354.7 M337.8 M111.6 M
Slightly volatile
Non Currrent Assets Other4 M6.9 M4.7 M
Pretty Stable
Cash And Short Term Investments1.3 B1.2 B424.5 M
Slightly volatile
Net Receivables20.1 M19.1 M10.2 M
Slightly volatile
Common Stock Total Equity58.5 K108.1 K67.2 K
Slightly volatile
Short Term Investments1.2 B1.1 B358.7 M
Slightly volatile
Other Current Assets18.4 M17.6 M6.8 M
Slightly volatile
Property Plant And Equipment Gross215.1 M204.9 M67.5 M
Slightly volatile
Total Current Assets1.3 B1.3 B441.6 M
Slightly volatile
Short Term Debt36.8 M35.1 M11.1 M
Slightly volatile
Common Stock128.9 K135.7 K45.3 M
Very volatile
Property Plant Equipment97.1 M92.5 M32.3 M
Slightly volatile
Capital Surpluse921.5 M1.7 B929.3 M
Slightly volatile
Short and Long Term Debt8 M13.2 M5.4 M
Slightly volatile
Long Term Debt Total43.5 M73.4 M37.3 M
Slightly volatile
Non Current Liabilities Other374 M689.1 M242.6 M
Slightly volatile
Net Invested Capital305.1 M600 M242.1 M
Slightly volatile
Net Working Capital1.1 B1.1 B446.3 M
Slightly volatile
Capital Stock91.5 K135.7 K73.5 K
Slightly volatile
Capital Lease Obligations100.2 M151.3 M50.6 M
Slightly volatile

Cytokinetics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Interest Expense104.5 M99.5 M31.5 M
Slightly volatile
Other Operating Expenses669.8 M637.9 M232.7 M
Slightly volatile
Research Development409.8 M390.3 M148 M
Slightly volatile
Total Operating Expenses260 M247.6 M87.5 M
Slightly volatile
Selling General Administrative260 M247.6 M84.9 M
Slightly volatile
Total Revenue32.5 M21.2 M35.6 M
Pretty Stable
Depreciation And Amortization11.5 M11 M4.4 M
Slightly volatile
Cost Of Revenue409.8 M390.3 M150 M
Slightly volatile
Preferred Stock And Other Adjustments1.7 M1.2 M1.5 M
Slightly volatile
Interest Income62.2 M59.3 M13.4 M
Slightly volatile
Reconciled Depreciation11.5 M11 M3.9 M
Slightly volatile

Cytokinetics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow136.9 M130.4 M63.7 M
Slightly volatile
Depreciation11.5 M11 M3.8 M
Slightly volatile
Capital Expenditures5.2 M4.5 M6.1 M
Pretty Stable
Total Cash From Financing Activities1.1 B1.1 B294.4 M
Slightly volatile
End Period Cash Flow56.3 M109.5 M62.6 M
Slightly volatile
Stock Based Compensation118.1 M112.5 M32.3 M
Slightly volatile
Change To Netincome94.9 M90.4 M31.7 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio269257125
Slightly volatile
Days Sales Outstanding299378112
Slightly volatile
Stock Based Compensation To Revenue5.04.771.7086
Slightly volatile
Capex To Depreciation0.350.372.613
Pretty Stable
EV To Sales305290136
Slightly volatile
Payables Turnover17.8519.1616.5338
Pretty Stable
Sales General And Administrative To Revenue11.0110.494.2977
Slightly volatile
Research And Ddevelopement To Revenue17.3616.538.0397
Slightly volatile
Capex To Revenue0.250.240.1777
Pretty Stable
Cash Per Share18.2211.0511.3447
Pretty Stable
Days Payables Outstanding20.719.7124.7564
Pretty Stable
Current Ratio5.745.557.4494
Very volatile
Receivables Turnover0.951.0972
Slightly volatile
Capex Per Share0.03810.04011.4094
Slightly volatile
Revenue Per Share0.180.192.7729
Slightly volatile
Interest Debt Per Share7.148.993.718
Slightly volatile
Debt To Assets0.530.510.3122
Slightly volatile
Graham Number5.115.385.926
Slightly volatile
Operating Cycle297378111
Slightly volatile
Days Of Payables Outstanding20.719.7124.7564
Pretty Stable
Ebt Per Ebit0.830.991.0634
Pretty Stable
Effective Tax Rate0.0050.0050.0044
Slightly volatile
Quick Ratio5.755.557.468
Very volatile
Net Income Per E B T0.820.961.0429
Slightly volatile
Cash Ratio0.580.611.7115
Slightly volatile
Days Of Sales Outstanding299378112
Slightly volatile
Fixed Asset Turnover0.110.127.7464
Slightly volatile
Debt Ratio0.530.510.3122
Slightly volatile
Price Sales Ratio269257125
Slightly volatile
Asset Turnover0.01440.01520.1469
Slightly volatile

Cytokinetics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap7.6 B7.3 B5.2 B
Slightly volatile
Enterprise Value334.5 M318.6 M295.5 M
Slightly volatile

Cytokinetics Fundamental Market Drivers

Cytokinetics Upcoming Events

6th of March 2024
Upcoming Quarterly Report
View
2nd of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
6th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Cytokinetics Financial Statements

Cytokinetics investors utilize fundamental indicators, such as revenue or net income, to predict how Cytokinetics Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue60.2 M63.2 M
Total Revenue21.2 M32.5 M
Cost Of Revenue390.3 M409.8 M
Stock Based Compensation To Revenue 4.77  5.00 
Sales General And Administrative To Revenue 10.49  11.01 
Research And Ddevelopement To Revenue 16.53  17.36 
Capex To Revenue 0.24  0.25 
Revenue Per Share 0.19  0.18 
Ebit Per Revenue(33.38)(31.71)

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Prophet
When determining whether Cytokinetics is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Cytokinetics Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Cytokinetics Stock. Highlighted below are key reports to facilitate an investment decision about Cytokinetics Stock:
How To Invest In Cytokinetics
Details
Is Cytokinetics Stock a good investment?
Details
What is Cytokinetics' Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of Cytokinetics Correlation against competitors.
For more information on how to buy Cytokinetics Stock please use our How to buy in Cytokinetics Stock guide.
You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cytokinetics. Projected growth potential of Cytokinetics fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Cytokinetics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share
(6.30)
Revenue Per Share
0.733
Quarterly Revenue Growth
3.181
Return On Assets
(0.25)
Return On Equity
(5.72)
The market value of Cytokinetics is measured differently than its book value, which is the value of Cytokinetics that is recorded on the company's balance sheet. Investors also form their own opinion of Cytokinetics' value that differs from its market value or its book value, called intrinsic value, which is Cytokinetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cytokinetics' market value can be influenced by many factors that don't directly affect Cytokinetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
It's important to distinguish between Cytokinetics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Cytokinetics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Cytokinetics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY